

Media Guide



TABLE OF CONTENTS PAGE

Who is the ISTH?	1
ISTH leadership	2
ISTH 2023 overview and	3-6
media program	
In the news	7–8
ISTH 2024 overview	12









WHO IS THE ISTH?

The International Society on Thrombosis and Haemostasis (ISTH) first and foremost stands for leading edge science. As a global membership community of specialists in bleeding and clotting disorders, the Society is dedicated to transformative scientific discoveries to advance clinical practice and improve the lives of millions of people worldwide.

The ISTH Mission

The International Society on Thrombosis and Haemostasis (ISTH) advances the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis.

ISTH PROGRAMS

The ISTH has programs aimed at advancing research, education, and clinical care in the fields of thrombosis and hemostasis. Some of the major programs of the ISTH include:

- 1. Scientific and Standardization Committees (SSCs)
- 2. Meetings and Congresses
- 3. Awards and Grants
- 4. Educational Programs including the ISTH Academy
- 5. Publications: Journal of Thrombosis and Haemostasis and Research and Practice in Thrombosis and Haemostasis (open access)
- 6. World Thrombosis Day
- 7. Public Affairs Program

Overall, the ISTH is dedicated to advancing the understanding and treatment of thrombosis and hemostasis through research, education and collaboration.

Membership

The ISTH has nearly 7,000 members from 120 countries around the world.

Learn more online at www.ISTH.org.





ISTH LEADERSHIP

The Council is the governing body of the ISTH. It authorizes and exercises all corporate powers of the Society and oversees all activities.



Flora Peyvandi, M.D., Ph.D. ISTH President for the 2022-2024

Flora Peyvandi, M.D., Ph.D., is a professor of internal medicine at the University of Milan and the Director of the Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center at the Internal Medicine-Hemostasis and Thrombosis Unit of the IRCCS Maggiore Hospital in Milan, Italy. Her research, as highlighted by her numerous publications, has focused on the investigation of molecular mechanisms of coagulation disorders and on the immunogenicity of coagulation products.



Pantep Angchaisuksiri, M.D. Elected ISTH President for the 2024-2026

Pantep Angchaisuksiri, M.D., is a Professor of Medicine and Chief of the Haemostasis and Thrombosis Unit at Ramathibodi Hospital of Mahidol University, in Bangkok, Thailand. He also holds posts of Adjunct Associate Professor of Medicine at the University of North Carolina at Chapel Hill, School of Medicine, and is co-director of the Bangkok International Haemophilia Training Centre of the World Federation of Haemophilia.



Thomas Reiser ISTH Executive Director

Serving as the Executive Director of the ISTH since May 2011, Thomas Reiser works closely with the ISTH Board to set the Society's strategy, organizational development and effective governance. He has led over ten international scientific-medical professional organizations with ultimate responsibility for strategy, corporate relations, educational and publishing programs and meetings around the world.





ISTH 2023 OVERVIEW

The annual ISTH Congress is the premier event in the field of thrombosis and hemostasis featuring the latest scientific breakthroughs and clinical updates. Clinicians, researchers, educators, students/trainees, allied healthcare professionals and industry partners attend these events to exchange the latest in scientific innovation and to advance the overall understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The event also features the annual meeting of the Society's Scientific and Standardization Committee (SSC), recognizing the value of the SSC's work and its highly important applications.

ISTH 2023, the XXVII Congress of the International Society on Thrombosis and Haemostasis, is scheduled to take place June 24 - 28, 2023, in Montréal, Canada.

ISTH 2023 will bring together leading experts and professionals in the field of thrombosis and haemostasis from around the world to share their latest research findings, discuss emerging trends and challenges, and collaborate on innovative solutions. Attendees can expect a diverse program of presentations, interactive sessions, and workshops covering a broad range of topics such as thrombosis prevention, diagnosis and treatment, hemophilia, platelet disorders, and much more.

In addition, ISTH 2023 participants will have ample opportunities to network, exchange ideas, and explore the vibrant city of Montréal. The Congress promises to be an exciting and insightful event for anyone interested in the latest advances in thrombosis and haemostasis research and practice.

To learn more about ISTH 2023, the program, events and activities, visit www.ISTH2023.org and download the Congress App.





ISTH 2023 LEADERSHIP

ISTH 2023 Congress Co-Chairs:



Susan Kahn, M.D. ISTH 2023 Congress Co-Chair

Susan R. Kahn, M.D., is a clinical epidemiologist and internist based at the Jewish General Hospital in Montreal, where she is the founder and director of the Centre of Excellence in Thrombosis and Anticoagulation Care (CETAC). She is a Professor in the Department of Medicine, McGill University, where she also holds the position of Associate Chair-Research. She is co-Director of the CanVECTOR Network, a Canadian national venous thromboembolism research and training network, and she holds a Tier 1 Canada Research Chair in Venous Thromboembolism.



Marc Rodger, M.D. ISTH 2023 Congress Co-Chair

Marc Rodger, M.D., is the Chair of the McGill University Department of Medicine, Physician-in-Chief, McGill University Health Center and the Harry Webster Thorp Professor of Medicine. His teaching, clinical care and research focuses on venous thrombosis. Rodger co-founded, co-directs and obtained CIHR funding for CanVECTOR (Canadian Venous Thrombosis Clinical Trials and Outcomes Research) Network. Rodger also founded and is past Chair of INVENT (International Network of Venous Thrombosis Clinical Research Networks). INVENT includes 10 national research networks with over 450 investigators in over 150 research sites throughout the world.





ISTH 2023 MEDIA PROGRAM

The ISTH welcomes the interest of press covering thrombotic and bleeding disorders and is happy to provide assistance to journalists attending the Congress or using the Congress website as a resource in their coverage.

Overall Regulations: Any media outlet or press representative (journalists, reporters, photographers, etc.) wishing to participate an ISTH event and/or to obtain official press releases from the ISTH Press Office must adhere to the ISTH Media and Embargo Policy.

Abstracts	Embargo Lift
Abstracts accepted as a(n): Oral Communication (prefix OC) Poster (prefix PB) Nurse Forum (prefix NUR) Publication Only (prefix PO)	Friday, June 9, 2023 at 9:00 a.m. Eastern Standard Time (U.S. EST)
Late-Breakthrough Oral Communication abstracts (prefix LBA)	Late Breakthrough Press Conference on Tuesday, June 27 at 2:45 p.m. (U.S. EST)

For all press inquires or questions, please contact:

Melissa DiMercurio ISTH 2023 Media Relations Manager Melissa_DiMercurio@isth.org

Quick Links to Resources:

- ISTH 2023 Program
- Embargo Policy
- Photo/Recording Policy
- Social Media
- Registration FAQs





VISIT THE ISTH PRESS ROOMS

The ISTH will have an onsite press room dedicated to helping journalists get the resources they need as well as conduct interview with key leadership and global experts.

The Press Office is located on the 5th Floor in Room 521B. All members of the press are invited to utilize this room as an onsite working station.

The Press Briefing Room is also located on the 5th Floor in Room 521B. This room is being utilized for scheduled video briefings and will be the location of our Late-Breakthrough Press Conference.

Save the Date:

ISTH 2023 Congress Late-Breakthrough Press Conference

Tuesday, June 27 2:45PM -3:45PM Press Briefing Room Floor 5, Room 521B

Press Conference will highlight several late-breakthrough abstracts giving press the opportunity to interview the authors.







PRESS CONFERENCE AGENDA

Welcome and Overview of ISTH 2023 Scientific Program: Margaret Rand, Ph.D., Hospital for Sick Children and University of Toronto, Ontario, Canada; and an Executive Member of the Local Organizing Committee for Congress Montréal.	2:45-2:55 p.m.
Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA) Andreas Tiede, M.D., Ph.D., Hannover Medical School, Hannover, Germany	2:55-3:05 p.m.
Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis Amelia Haj, M.D., Ph.D., Massachusetts General Hospital, Massachusetts, United States	3:05-3:15 p.m.
Distinct Antibody Groups in Patients With Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and their Clinical Implications Ishac Nazy,Ph.D., McMaster University, Ontario, Canada	3:15-3:25 p.m.
Targeted thromboprophylaxis in patients with lower limb trauma requiring immobilization: stepped wedge randomized trial Delphine Douillet, M.D., Ph.D., Emergency Department, Centre Hospitalier Universitaire d'Angres, CHU Angers, Angers, France	3:25-3:35 p.m.
Questions & Answers	3:35-3:45 p.m.





ISTH 2023 Congress Unveils Late-Breakthrough Abstract Titles to be Presented in Montréal Showcasing Latest Science and Groundbreaking Research

Press conference with scientific highlights will take place at Palais des Congrès de Montréal

CANADA, June 14, 2023 – Today, <u>the International Society on Thrombosis and Haemostasis (ISTH)</u> announces that all ISTH 2023 Congress (June 24-28, 2023) abstracts are public online, including late-breakthrough abstracts titles, to give a detailed glimpse into the posters, presentations and plenaries that will be presented at the Congress in Montréal, Canada.

In addition to these announcements, the ISTH 2023 press conference will take place on Tuesday, June 27, from 2:45 p.m.- 3:45 p.m. (EST) in the press briefing room located on the fifth floor in room 521B at the Palais des Congrès de Montréal. The press conference will be moderated by Margaret Rand, Ph.D., Professor in the Department of Laboratory Medicine and Pathobiology of Biochemistry and of Pediatrics at the University of Toronto, Senior Associate Scientist and Co-Director of the Clinical Hemostasis and Thrombosis Research Laboratory at the Hospital for Sick Children and Executive Member of the Local Organizing Committee for the ISTH 2023 Congress.

At the ISTH 2023 Congress, thousands of the world's leading experts on thrombosis, hemostasis and vascular biology convene to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes the latest scientific discourse and advancement in the field.





The following late-breakthrough abstracts will be highlighted during the ISTH 2023 press conference:

- Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA), Andreas Tiede, M.D., Ph.D., Hannover Medical School, Hannover, Germany
- Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis, Amelia Haj, M.D., Ph.D., Massachusetts General Hospital, Massachusetts, United States
- Targeted thromboprophylaxis in patients with lower limb trauma requiring immobilization: stepped wedge randomized trial, Delphine Douillet, M.D., Ph.D., Emergency Department, Centre Hospitalier Universitaire d'Angres, CHU Angers, Angers, France
- Distinct Antibody Groups in Patients With Vaccine-Induced Immune Thrombotic
 Thrombocytopenia (VITT) and their Clinical Implications Ishac Nazy, Ph.D., McMaster
 University, Ontario, Canada

Due to limited space, please RSVP to attend the ISTH 2023 press conference: https://www.isth2023.org/event-details/isth-2023-congress-late-breakthrough-press-conference

To see a full list of the late-breakthrough abstracts that will be presented throughout the Congress, continue reading below.





Sunday, June 25, 2023

- Efanesoctocog Alfa Prophylaxis for Previously Treated Patients < 12 Years of Age With Severe Hemophilia A by Lynn Malec, M.D., Versiti Medical Sciences Institute, Wisconsin, United States Late Breakthrough Session I, 10:45 a.m., Room 517
- Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA) by Andreas Tiede, M.D., Ph.D., Hannover Medical School, Hannover, Germany Late Breakthrough Session I, 11:00 a.m., Room 517
- Factor XIII 24-Hour Trajectory Analysis in Severely Injured Patients: Post-Hoc Analysis
 of the Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Study by
 Johana Gomez Builes, University of Toronto, Toronto, Canada Late Breakthrough
 Session I, 11:15 a.m., Room 517
- Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis by Amelia Haj, M.D., Ph.D., Massachusetts General Hospital, Massachusetts, United States – Late Breakthrough Session I, 11:30 a.m., Room 517
- Effect of the P-selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial by Charles Lowenstein, M.D., The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Late Breakthrough Session I, 11:45 a.m., Room 517

Tuesday, June 27, 2023

- Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial by Robert McBane, M.D., Mayo Clinic, Minnesota, United States – Late Breakthrough Session II, 10:45 a.m., Room 517
- Prevention of Symptomatic Venous Thromboembolism with Low-Molecular-Weight Heparin in Hospitalized Older Adult Medical Patients: a Randomized Placebo-Controlled Trial by Grégoire Le Gal, M.D., Ph.D., Ottawa Hospital Research Institute, Ottawa, Canada Late Breakthrough Session II, 11:00 a.m., Room 517





- Targeted thromboprophylaxis in patients with lower limb trauma requiring immobilization: stepped wedge randomized trial by Delphine Douillet, M.D., Ph.D., Emergency Department, Centre Hospitalier Universitaire d'Angres, CHU Angers, Angers, France – Late Breakthrough Session II, 11:15 a.m., Room 517
- Anti-platelet factor 4 induced immunothrombosis independent of heparin or vaccination by Andreas Greinacher, M.D., Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany – Late Breakthrough Session II, 11:30 a.m., Room 517
- Distinct Antibody Groups in Patients With Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and their Clinical Implications by Ishac Nazy, Ph.D., McMaster University, Ontario, Canada – Late Breakthrough Session II, 11:45 a.m., Room 517

Full details of late-breakthrough abstracts are embargoed until time of presentation, after which they will become available via the ISTH 2023 program.

With a diverse and extensive range of highly anticipated topics, members of the press are encouraged to reach out to ISTH Media Relations Manager, Melissa DiMercurio, at melissa_dimercurio@isth.org, to schedule individual interviews with presenters or ISTH leadership.

For more information about the ISTH 2023 Congress, visit www.isth2023.org and for all other media needs, visit the virtual press room: www.isth2023.org/mediaroom.

About the International Society on Thrombosis and Haemostasis (ISTH) Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis. ISTH is an international medical-scientific professional membership organization with more than 7,000 clinicians, researchers, and educators working together to improve the lives of patients in more than 110 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees, and World Thrombosis Day on October 13. Visit ISTH online at www.isth.org.



ABOUT THE CONGRESS

Get ready for an electrifying experience at ISTH 2024 in Bangkok, Thailand from June 22 - 26, 2024!

Brace yourself for the premier medical and scientific event in the field of thrombosis and hemostasis, where the most brilliant minds, distinguished clinicians, pioneering researchers, and promising early career scientists from across the globe will converge.

At ISTH 2024, prepare to be captivated as delegates present groundbreaking discoveries and unveil cutting-edge advancements that push the boundaries of scientific knowledge. Witness the rapid translation of these scientific breakthroughs into innovative approaches for the diagnosis and treatment of thrombotic and bleeding disorders. This thrilling exchange of expertise promises to revolutionize patient care and reshape the future of thrombosis and hemostasis medicine.

With a targeted attendance of approximately 6,000 delegates, ISTH 2024 in Bangkok will be a dynamic and vibrant gathering of the world's foremost experts in the field. Immerse yourself in a bustling atmosphere filled with intellectual stimulation, collaborative discussions, and unrivaled networking opportunities.

Join forces with like-minded professionals who share your passion and dedication, as together, we strive to enhance patient outcomes and shape the future of thrombosis and hemostasis.

www.ISTH2024.org





Thailand offers an extraordinary blend of vibrant culture, warm hospitality, and breathtaking landscapes. With its bustling cities, world-class infrastructure, and renowned cuisine, Thailand provides the perfect backdrop for successful professional gatherings. From the bustling streets of Bangkok to the serene beaches of Phuket, this enchanting country is an ideal place to combine business with pleasure, ensuring a memorable and productive experience for all attendees.

